Lumican Activators
Lumican is a small leucine-rich proteoglycan primarily found in the extracellular matrix (ECM) of various tissues, including the cornea, skin, and heart. It plays a crucial role in regulating ECM organization, collagen fibrillogenesis, and tissue integrity. Lumican interacts with collagen fibers and other ECM components, such as fibronectin and elastin, through its leucine-rich repeat (LRR) domains, thereby influencing matrix assembly and stability. Additionally, Lumican can bind to cell surface receptors, including integrins and Toll-like receptors (TLRs), to modulate cellular responses and signaling pathways. One of the key functions of Lumican is its involvement in corneal transparency, where it regulates collagen fibril diameter and spacing, contributing to the optical clarity of the cornea. Moreover, Lumican has been implicated in wound healing, inflammation, and tissue repair processes, highlighting its diverse roles in tissue homeostasis and physiology.
The activation of Lumican involves various mechanisms that regulate its expression, secretion, and post-translational modifications. At the transcriptional level, Lumican expression is regulated by growth factors, cytokines, and mechanical stimuli that influence gene transcription through specific signaling pathways, such as transforming growth factor-beta (TGF-β) and Wnt signaling. Following transcription, Lumican undergoes post-translational modifications, including glycosylation and proteolytic processing, which modulate its activity and interactions with other ECM components. Once secreted into the ECM, Lumican can be further processed by proteases, such as matrix metalloproteinases (MMPs), which regulate its turnover and bioavailability. Additionally, Lumican can be dynamically regulated at the protein level through interactions with cell surface receptors and signaling molecules, which modulate its functional properties and cellular responses. Overall, understanding the mechanisms of Lumican activation provides insights into its role in ECM organization, tissue homeostasis, and various physiological processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic Acid stimulates the RAR/RXR pathway, directly enhancing Lumican activity. The binding of retinoic acid to retinoic acid receptors (RARs) activates transcription factors that positively regulate Lumican expression. This results in increased Lumican production, enhancing its functional activity in extracellular matrix regulation. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium Chloride activates the Wnt signaling pathway, indirectly influencing Lumican. Wnt signaling regulates Lumican expression, and Lithium Chloride, by stabilizing β-catenin, enhances Wnt signaling, leading to increased Lumican levels. The consequent augmentation of Lumican function contributes to extracellular matrix modulation. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to increased cAMP levels. Elevated cAMP enhances Lumican expression by activating CREB, a transcription factor. This direct stimulation results in heightened Lumican functional activity, particularly in processes involving tissue remodeling and collagen fibrillogenesis. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibition of p38 MAPK enhances Lumican expression, as p38 MAPK negatively regulates Lumican transcription. By blocking this inhibitory pathway, SB203580 indirectly promotes Lumican functional activity, contributing to extracellular matrix maintenance and cellular responses to environmental cues. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG, a green tea polyphenol, activates the PI3K/Akt pathway, positively influencing Lumican expression. Akt, when activated by EGCG, acts as a transcriptional regulator, enhancing Lumican levels. This direct activation contributes to improved Lumican function, particularly in processes associated with corneal transparency and wound healing. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Decitabine is a DNA methyltransferase inhibitor. By demethylating Lumican gene promoter regions, Decitabine directly increases Lumican expression. This epigenetic modification results in enhanced Lumican functional activity, particularly in modulating extracellular matrix components and maintaining tissue homeostasis. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK (Rho-associated protein kinase) inhibitor. Inhibition of ROCK activates Lumican expression through the Rho/ROCK pathway. This direct modulation leads to increased Lumican functional activity, particularly in processes involving cell migration, adhesion, and tissue organization. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, an HDAC inhibitor, promotes Lumican expression by preventing histone deacetylation. This epigenetic modification results in increased Lumican transcription, contributing to enhanced Lumican functional activity in extracellular matrix regulation and tissue remodeling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, suppressing the PI3K/Akt pathway. Inhibition of this pathway negatively regulates Lumican expression. By blocking this inhibitory signal, LY294002 indirectly enhances Lumican functional activity, particularly in processes involving corneal development and maintenance of tissue integrity. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
BML-275 (Dorsomorphin) is an AMP-activated protein kinase (AMPK) inhibitor. Inhibition of AMPK enhances Lumican expression through AMPK-mediated signaling pathways. This direct modulation results in increased Lumican functional activity, particularly in processes associated with corneal development and extracellular matrix regulation. | ||||||